A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer

Lessons Learned Concurrent ETBX‐011, ETBX‐051, and ETBX‐061 can be safely administered to patients with advanced cancer. All patients developed CD4+ and/or CD8+ T‐cell responses after vaccination to at least one tumor‐associated antigen (TAA) encoded by the vaccine; 5/6 patients (83%) developed MUC1...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2020-06, Vol.25 (6), p.479-e899
Hauptverfasser:	Gatti‐Mays, Margaret E., Redman, Jason M., Donahue, Renee N., Palena, Claudia, Madan, Ravi A., Karzai, Fatima, Bilusic, Marijo, Sater, Houssein Abdul, Marté, Jennifer L., Cordes, Lisa M., McMahon, Sheri, Steinberg, Seth M., Orpia, Alanvin, Burmeister, Andrea, Schlom, Jeffrey, Gulley, James L., Strauss, Julius
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical Trial Results
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!